Alphabet's Verily Offers AI-Driven Consumer Health App
By Kelly Cloonan
Verily, a subsidiary of Alphabet, is offering a new consumer health app driven by artificial intelligence in an effort to provide more personalized treatment recommendations.
The data platform and technology company said Friday the app will allow licensed clinicians to review patient records across multiple providers and health systems to provide users with personalized recommendations.
Users will also be able to ask questions about their health records to an AI assistant, receive feedback and nutrition tips by logging their meals, and participate in a Verily health study.
The app aims to offer a simpler, more personalized and data-driven healthcare solution, the company said.
Members of Verily's Lightpath personalized care program, which is subsidized by employers, payers, and pharmacy benefit managers, will also use the app.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
October 17, 2025 12:45 ET (16:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
2 Undervalued Stocks to Buy Before They Rebound
United States